Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SHORTER trial: what clinicians have said so far
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
- NCT04422132 ↗
- Active, not recruiting
- Weill Medical College of Cornell University
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on SHORTER yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SHORTER so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- 5 days Radiation Therapy (32.5 Gy in 5 fractions); 20 days Radiation therapy (55 Gy in 20 fractions)
- Arms
- ARM 1 - 2 weeks · Active comparator
- ARM 2 - 4 weeks · Active comparator
- Enrollment
- 137
- Primary outcomes
- Change in the Number of Patient-reported GI Symptoms Using the Expanded Prostate Cancer Index Composite (EPIC)
- Change in the Number of Patient-reported GI Symptoms Using the Expanded Prostate Cancer Index Composite (EPIC)
- Change in the Number of Patient-reported GU Symptoms Using the Expanded Prostate Cancer Index Composite (EPIC)
- Change in the Number of Patient-reported GU Symptoms Using the Expanded Prostate Cancer Index Composite (EPIC)
- Sponsor
- Weill Medical College of Cornell University with Viewray Inc.
- Start
- Sep 24, 2020
- Primary completion
- Dec 31, 2025
- Results posted
- Yes
- Registry record
- NCT04422132 · updated Oct 14, 2026
Publications
linked from the registry- Marciscano AE, Wolfe S, Zhou XK, Barbieri CE, Formenti SC, Hu JC, Molina AM, Nanus DM, Nauseef JT, Scherr DS, Sternberg CN, Tagawa ST, Nagar H. Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER). BMC Cancer. 2023 Aug 22;23(1):781. doi: 10.1186/s12885-023-11278-3. PubMed 37608258